HAL ALLERGIE GMBH
Pharmaceutical Companies · Düsseldorf
HAL ALLERGIE GMBH is a pharmaceutical company based in Düsseldorf, North Rhine-Westphalia, Germany. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
HAL ALLERGIE GMBH Address & Contact
Company profile
1948
Founded
500+ (HAL Allergy global)
Employees
HAL Allergy GmbH at a Glance
HAL Allergy GmbH, based in Düsseldorf, North Rhine-Westphalia, is the German subsidiary of HAL Allergy, a leading Dutch pharmaceutical company specializing in allergology and allergen immunotherapy. The company was founded in 1948 and has made a name for itself as a significant provider of therapies for the treatment of allergic conditions. At the heart of the corporate strategy is the development and provision of innovative solutions for patients suffering from allergic reactions.
Field of Activity and Products
HAL Allergy offers a comprehensive portfolio of allergen immunotherapy products. These products aim to treat allergies, including widespread forms such as hay fever, house dust mite allergy, and insect venom allergy. The company conducts a range of highly effective specific immunotherapies (SIT), which are available in both sublingual and subcutaneous forms.
Among the most well-known products are the ALK Abello collaboration products, which stand out for their high-quality formulation and effectiveness, as well as a selection of HAL's proprietary products. These therapies are prescribed exclusively by qualified professionals such as allergists and ENT doctors, and are conducted in specialized practices to ensure patient-centered treatment approaches. The products are manufactured under strict regulatory requirements and are examined and approved by relevant authorities, including the European Medicines Agency (EMA).
Regulatory Classification
HAL Allergy GmbH operates within the framework of strict regulatory guidelines that are specific to the pharmaceutical industry. Each product from HAL Allergy undergoes extensive clinical trials to ensure safety and efficacy. Post-marketing surveillance (pharmacovigilance) ensures that data on treatment outcomes is continuously collected even after approval, in order to maintain product quality and address potential risks early on.
Regional Commitment and Importance
The position of HAL Allergy in Düsseldorf is shaped not only by the corporate structure but also by its regional significance for the pharmaceutical industry. North Rhine-Westphalia is a central location for pharmaceutical companies in Germany and provides a dynamic environment for research and development.
Düsseldorf is characterized by good connections to research institutions and universities, allowing HAL Allergy to benefit from synergies with science and technology. This commitment not only fosters the company's innovative capacity but also the development of new, effective therapies for allergy sufferers.
Special Features and Future Perspectives
HAL Allergy focuses on further strengthening its position in the field of allergology. The company continuously invests in research and development to explore new therapeutic approaches and optimize existing products. A particular emphasis is placed on developing therapies that are both effective and comfortable for patients. This includes the further development of sublingual immunotherapy, which represents a less invasive treatment alternative to traditional injection methods.
In addition, HAL Allergy relies on close collaboration with healthcare institutions and professional societies to raise awareness about allergies and increase the availability of innovative treatment options. The company's future prospects are promising, especially given the increasing prevalence of allergies worldwide.
More information: Pharmaceutical companies in North Rhine-Westphalia or all pharmaceutical companies in Germany on Sanoliste.
```Frequently asked questions about HAL ALLERGIE GMBH
What does HAL ALLERGIE GMBH do?
HAL ALLERGIE GMBH hat sich als Pharmaundernehmen on the Behandlung of Allergien fokussiert. Sie stellt Tests her for the präzise Diagnose; behandelt with the Allergen-Immuntherapie the Ursache the Allergie and stellt Mittel for the subkutane and sublinguale Immuntherapie zur Verfügung. Das zweite Standatn is the Erstellung of biotechnologischen productsn.
More Pharmaceutical Companies in Düsseldorf
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.